Incubated by Third Rock Ventures, Marea Therapeutics officially launched this week with a cardiometabolic disease pipeline led by MAR001, an anti-ANGPTL4 antibody that is in a phase 1b/2a study in ...

Morningstar brands and products Company Portfolio ...

SAN FRANCISCO, December 19, 2024--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next ...

"Momentum continues to build at Marea as we advance our lead program, MAR001, through clinical development," said Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea. "We are pleased to ...